



Saamya Biotech (India) Ltd.

CIN: L24239AP2002PLC039449

November 14, 2018

To

Corporate Relations Department,
BSE LTD,
P J Towers,
Dalal Street,
Mumbai - 400001.

Sirs,

Sub: Q2 Unaudited Financial Results – Reg...

Ref: Scrip Code – 532905


Please find herewith attached Un-audited financial results for the Second quarter ending 30th September 2018 along with Limited Review Report. The Board Meeting Commenced at 4 PM and concluded at 5:15 PM. Please take on record the same.

Thanking You,

For SAAMYA BIOTECH (INDIA) LIMITED

P. Hanumanth Rao

Director



Corporate Office: Plot No. 391- D, Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604.
Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9932 / 9241
Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com



M M REDDY & CO.,
Chartered Accountants

Phone : 040-23418836
040-40272617
Mobile : 98482 71555

LIMITED REVIEW REPORT

To,
The Board of Directors,
Saamya Biotech (India) Limited

We have reviewed the accompanying statement of Un-audited Financial Results of **Saamya Biotech (India) Limited** for the quarter ended **30th September, 2018** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14th November, 2018.

For **M. Reddy & Co.**
Chartered Accountants

M Madhusudhana Reddy
Partner
Membership No. 21305





Saamya Biotech (India) Ltd.

SAAMYA BIOTECH (INDIA) LTD							
Statement of Un-Audited Results for the Quarter ended 30.09.2018							
S.No.	Particulars	Quarter Ended			Half year Ended		Year Ended
		30.09.2018 Un-Audited	30.06.2018 Un-Audited	30.09.2017 Un-Audited	30.09.2018 Un-Audited	30.09.2017 Un-Audited	31.03.2018 Audited
I.	Revenue from Operations	-	-	-	-	-	-
II.	Other Income	-	-	-	-	-	-
III.	Total income (I+II)	-	-	-	-	-	-
IV.	Expenses						
	(a) Cost of Materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expense	0.30	0.36	0.53	0.66	1.09	2.03
	(e) Finance Cost	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(h) Other expenses	0.25	0.25	0.25	0.50	0.50	1.00
	Total Expenses	0.55	0.61	0.78	1.16	1.59	3.03
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	(0.55)	(0.61)	(0.78)	(1.16)	(1.59)	(3.03)
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	(0.55)	(0.61)	(0.78)	(1.16)	(1.59)	(3.03)
VIII.	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX.	Net Profit / (Loss) after Tax (VII-VIII)	(0.55)	(0.61)	(0.78)	(1.16)	(1.59)	(3.03)
X.	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XI.	Total Comprehensive Income	(0.55)	(0.61)	(0.78)	(1.16)	(1.59)	(3.03)
XII.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25
XIII.	Earnings Per Equity Share of face value of Rs.10/- each						
	a) Basic & Diluted (In Rs.)	(0.00)	(0.00)	(0.00)	(0.00)	(0.01)	(0.01)

Date: 14.11.2018
Place: Hyderabad

For SAAMYA BIO TECH (INDIA) LIMITED

Dr. Y. Manivardhan Reddy
Managing Director


NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.11.2018
- These results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
- The results are also available on the website of the Company www.saamyabiotech.com.
- The Company is engaged in "Research and Development of Bio-technology Products" operating hence there are no separate reportable segments as per Ind AS -108

Station: Hyderabad
Date : 14.11.2018

For SAAMYA BIO TECH (INDIA) LIMITED

Dr. Y. Manivardhan Reddy
Dr. Y. Manivardhan Reddy
Managing Director



Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604.
Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Website: www.saamyabiotech.com


Regd. Office: Suite 104-106. Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241
Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com

SAAMYA BIOTECH (INDIA) LTD
Balance Sheet as at 30th September 2018

Amount in Lakhs

Particulars		As at 30-09-2018	As at 31-03-2018
I	ASSETS:		
1	NON-CURRENT ASSETS:		
	(a) Property, Plant and Equipment	17.27	17.27
	(b) Capital work-in-progress	1,825.99	1,825.99
	(c) Investment Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible Assets	-	-
	(f) Intangible Assets under development	-	-
	(g) Biological Assets other than bearer plants	-	-
	(h) Financial Assets	-	-
	(i) Investments	-	-
	(ii) Loans	15.99	15.99
	(iii) Others	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	0.89	0.89
		1,860.13	1,860.13
2	CURRENT ASSETS:		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	1,860.76	1,860.76
	(iii) Cash and cash equivalents	0.87	0.87
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans	65.51	65.51
	(vi) Others (to be specified)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other current assets	-	-
		1,927.15	1,927.15
	TOTAL	3,787.28	3,787.28
II	EQUITY AND LIABILITIES:		
1	EQUITY:		
	(a) Equity Share Capital	2,488.25	2,488.25
	(b) Other Equity	-3,831.05	-3,829.89
		-1,342.80	-1,341.64
2	LIABILITIES:		
i	NON-CURRENT LIABILITIES:		
	(a) Financial Liabilities		
	(i) Borrowings	324.01	324.01
	(ii) Trade Payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (Net)	-	-
	(d) Other non-current liabilities	-	-
		324.01	324.01
ii	CURRENT LIABILITIES:		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (c))	4,681.66	4,681.66
	(b) Other current liabilities	1.16	-
	(c) Provisions	7.87	7.87
	(d) Current Tax Liabilities (Net)	115.38	115.38
		4,806.07	4,804.91
	TOTAL	3,787.28	3,787.28

Date: 14.11.2018
Place: Hyderabad



For SAAMYA BIOTECH (INDIA) LTD

Dr. Y. Manivardhan Reddy
Dr. Y. Manivardhan Reddy
Managing Director